Vivoryon Therapeutics AG Stock Euronext Amsterdam
Equities
DE0007921835
Biotechnology & Medical Research
Sales 2023 | -3.62K -3.88K | Sales 2024 * | - | Capitalization | 23.33M 25M |
---|---|---|---|---|---|
Net income 2023 | -28M -30.01M | Net income 2024 * | -18M -19.29M | EV / Sales 2023 | -53,497 x |
Net cash position 2023 | 18.52M 19.85M | Net cash position 2024 * | 19.55M 20.95M | EV / Sales 2024 * | - |
P/E ratio 2023 |
-7.27
x | P/E ratio 2024 * |
-1.25
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.82% |
Latest transcript on Vivoryon Therapeutics AG
Managers | Title | Age | Since |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 18-08-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 06-12-31 | |
Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.84B | |
+46.85% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |